You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

211 Results
Drug
Other Name(s): Afinitor®
Dec 1969
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
ODB - General Benefit
    exemestane
Regimen
Cancer Type:
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Drug
Other Name(s): Elrexfio™
Sep 2025
Guidelines and Advice
Updated
Jan 2026
Regimen
Cancer Type:
Central Nervous System
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Mar 2026
Drug
Other Name(s): Zolinza®
Mar 2026

Pages